Roger Perlmutter, 2016 Institute for Systems Biology via Youtube
King Keytruda flounders in another pivotal cancer study. And that may spur doubts about Merck's staying power
The king of the PD-(L)1 class is seeing a few cracks start to appear in the crown.
Merck reported Tuesday evening that its Phase III …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
